Keynote Speaker

Friday, June 13th 2025
SESSION V: PRECISION LIQUID DIAGNOSTICS

4.00 - 4.35 pm: KEYNOTE: "The Utility of Liquid Biopsy in Immuno-Oncology: A Focus on Circulating Tumour Cells"

Catherine Alix-Panabières, University Medical Centre of Montpellier (CHU)

Thursday, June 12th 2025
SESSION III: COMPUTATIONAL BIOLOGY & MACHINE LEARNING IN CANCER
4.50 - 5.25 pm: KEYNOTE: "AI Model Accurately Predicts Endometrial Cancer Recurrence"
 

Thursday, June 12th 2025
SESSION II: TRENDS IN CANCER EPIDEMIOLOGY - EARLY ONSET CANCER
11.45 am – 12.15 pm: KEYNOTE: "Evidence for Rising Incidence Rates of Early Onset Colorectal Cancer – a Global Perspective"

Freddie Bray, The International Agency for Research on Cancer (IARC)

Thursday, June 12th 2025
2.15 - 2.50 pm: KEYNOTE: "The Gemelli Clinic Vision on AI/Radiomics in Connection with Surgery"

Thursday 12th June 2025
SESSION I: WHAT´S NEXT IN IMMUNO ONCOLOGY?
9.15 - 9.50 am: KEYNOTE: "Concepts to Enable Immunotherapy in CRC"

Colorectal cancer (CRC) is the third most common type of cancer and one of the most
common cause for cancer-associated deaths in industrial nations. Carcinogenesis in
general is not a cell autonomous process, but a complex interplay of much more major
players than just mutagenized, cancer-initiating cells. Particularly in CRC the
reciprocal interaction of cells within the tumor microenvironment (TME) markedly
influences all stages of tumorigenesis, and the plasticity of both tumor cells and
surrounding cells within the TME is driven to a large extent by inflammation. So far,
all CRC tumors that have been studied are associated with an inflammatory
environment (either preceding tumorigenesis, tumor-elicited or therapy-induced)
and over the recent 5 years our knowledge of how tumor cells communicate with
their tumor microenvironment in order to modulate inflammatory immune responses
to their needs, for example in order to suppress and escape anti-tumorigenic immune
responses, has significantly improved. Thus, a detailed understanding of the molecular
and cellular basis defining the immune pathogenesis of CRC will undoubtedly lead to
the development of novel and more efficient multi-modal therapeutic strategies that
go beyond conventional therapies targeting tumor cells only. Recent findings
regarding the modulation of an adaptive immune during CRC pathogenesis and
therapy will be discussed.

Florian R. Greten, Georg Speyer Haus, Institute for Tumor Biology and Experimental Therapy

Friday, June 13th 2025
SESSION VI: NOVEL TARGETS FRESH FROM THE BENCH... TO THE BEDSIDE
11.00 - 11.35 am KEYNOTE: Douglas Hanahan, EPFL, École polytechnique fédérale de Lausanne

 

Friday, June 13th 2025
SESSION IV: NOVEL THERAPEUTICS
9.00 – 9.35 am: KEYNOTE: "Mode of Action – How to Choose the Right Target?"

Professor Thomas Powles is the Chair of Barts Cancer Centre, London.  He leads the Experimental Cancer Medicine Centre and Biomedical Research Cancer Grants at Barts/QMUL. He has led 23 randomised cancer trials including studies which resulted in multiple EMA and FDA approvals. He has led clinical and high impact translational science projects. He has an H-index of 100 and has given plenary presentations at the major cancer meeting. Barts. He co-leads the Uromigos podcast and European Guidelines for GU cancer. He is editor in chief of the Annals of Oncology Journal . In 2023 he was selected a Nature’s 10 global scientist and in 2024 TIME magazines 100 healthcare list .